Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous close | 5,840.45 |
| Open | 5,802.00 |
| Bid | 5,812.00 x 0 |
| Ask | 5,816.50 x 0 |
| Day's range | 5,802.00 - 5,845.75 |
| 52-week range | 4,385.70 - 6,505.50 |
| Volume | |
| Avg. volume | 13,718 |
| Market cap | 965.738B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 17.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 40.00 (0.69%) |
| Ex-dividend date | 15 July 2024 |
| 1y target est | N/A |
- Business Wire
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
